title: Eligibility for allogeneic transplantation in very high risk childhood acute lymphoblastic leukemia: the impact of the waiting time.
abstract: The advantage of allogeneic transplant from compatible related donors versus chemotherapy in children with very-high-risk acute lymphoblastic leukemia in first complete remission was previously demonstrated in an international prospective trial. This study quantified the impact of time elapsed in first remission in the same cohort. Of 357 pediatric patients with very-high-risk acute lymphoblastic leukemia, 259 received chemotherapy, 55 transplantation from compatible related and 43 from unrelated donors. The 5-year disease-free survival was 44.2% overall and 42.5% for chemotherapy only patients. The chemotherapy conditional 5-year disease-free survival increased to 44.4%, 47.6%, 51.7%, and 60.4% in patients who maintained their first remission for at least 3, 6, 9, and 12 months respectively. The overall outcome was superior to that obtained with chemotherapy-only at any time-point. The relative advantage of transplant from compatible related donors in very-high-risk childhood acute lymphoblastic leukemia was consistent for any time elapsed in first remission.
authors.affiliation: Clinica Pediatrica Università degli Studi di Milano Bicocca, Ospedale San Gerardo, via Pergolesi 33, 20052 Monza, Milan, Italy. adriana.balduzzi@pediatriamonza.it
authors.forename: Adriana
authors.initials: A
authors.lastname: Balduzzi
authors.forename: Paola
authors.initials: P
authors.lastname: De Lorenzo
authors.forename: André
authors.initials: A
authors.lastname: Schrauder
authors.forename: Valentino
authors.initials: V
authors.lastname: Conter
authors.forename: Cornelio
authors.initials: C
authors.lastname: Uderzo
authors.forename: Christina
authors.initials: C
authors.lastname: Peters
authors.forename: Thomas
authors.initials: T
authors.lastname: Klingebiel
authors.forename: Jan
authors.initials: J
authors.lastname: Stary
authors.forename: Maria S
authors.initials: MS
authors.lastname: Felice
authors.forename: Edina
authors.initials: E
authors.lastname: Magyarosy
authors.forename: Martin
authors.initials: M
authors.lastname: Schrappe
authors.forename: Giorgio
authors.initials: G
authors.lastname: Dini
authors.forename: Helmut
authors.initials: H
authors.lastname: Gadner
authors.forename: Maria Grazia
authors.initials: MG
authors.lastname: Valsecchi
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000379:methods*; D002648:Child; D015331:Cohort Studies; D018572:Disease-Free Survival; D006801:Humans; D016130:Immunophenotyping; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000235:genetics / Q000473:pathology* / Q000628:therapy*; D011446:Prospective Studies; D012074:Remission Induction; D012306:Risk; D013997:Time Factors; D014178:Translocation, Genetic; D014184:Transplantation, Homologous / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents